Kornimate/medical-research-clean huggingface dataset:
estradiol, progesterone and endometrial thickness in frozen euploid embryo transfer

Conditions: Infertility; Preimplantation Genetic Diagnosis/Screening; Miscarriage

Summary: the development and improvement in preimplantation genetic diagnosis/screening (pgs) in association with the efficacy and security of vitrification and trophectoderm biopsy, more efficient stimulation schemes and laboratory improvements in culture and embryo selection have contributed to high success of the assisted reproductive technologies(art). transferring an euploid embryo avoids one of the main reasons of miscarriage and implantation failure ( rubio et al, 22016) and overcomes one of the most important confounding factors. usually, the transfer of euploid embryos is performed under standard hormone replacement therapy (hrt) and are referred to as fet-pgs cycles( frozen embryo transfer). the study of fet-pgs cycles with the transfer of a single euploid blastocyst is the best model for evaluation of the impact of the endometrial preparation . among factors influencing fet outcomes, patient's age, endometrial preparation, endometrium thickness, endometrial pattern, number and quality of embryos transferred , difficulty at et, recently p4 have received more attention . the importance of progesterone (p4) in embryo implantation has been widely studied. p4 plays an important role in endometrial gland formation, embryonic implantation and pregnancy maintenance, both in natural and artificial cycles.


Eligibility criteria:
inclusion criteria: * frozen embryo transfer (fet) of at least one single euploid embryo. * estradiol \> 75pg/ml. * progesterone \> 4 ng/ml. * endometrial thickness between 6 mm and 18 mm. exclusion criteria: * patients with fet of no diagnostic or mosaic embryos, or known uterine abnormality were excluded. * natura cycle protocol.
can beta-hydroxy-beta-methylbutyrate supplementation counteract muscle catabolism in critically ill patients?

Conditions: Critical Illness; Muscle Weakness

Summary: the rapid decline of muscle mass and function in mechanically ventilated critically ill patients is associated with prolonged length of mechanical ventilation, prolonged intensive care (icu) and hospital stay, increased icu and hospital mortality, and prolonged impairment in physical function and quality of life. high protein feeding only partially attenuates the muscle loss. the aim is to study the impact of hmb (3 g/day) on the muscle mass of the critically ill patients from day 4 of their admission to maximum 30 days, but at least for 10 days.

the rapid decline of muscle mass and function in mechanically ventilated critically ill patients is associated with poor outcome, and limitations of functional recovery. high protein feeding only partially attenuates the muscle loss. the aim is to study the impact of hmb (3 g/day) on the muscle mass of the critically ill patients from day 4 of their admission to maximum 30 days, but at least for 10 days. the study is testing a nutrition complement (hmb) that is included in feeding products registered for medical nutrition by swiss federal authorities, but who do not provide sufficient protein quantities. on days 4 and 15 after icu admission, specific investigations will include: ultrasound measurement of the muscle quadriceps femoris (csa), bioimpedance analysis (bia) of body composition, protein synthesis and catabolism using amino acid tracers. on d30 and d60: telephone contact to assess global health and mobility (sf-12).

Eligibility criteria:
inclusion criteria: * likely length of stay \>5 days * on mechanical ventilation * likely survival \>7 days * full treatment * functional gastro-intestinal tract * presence of a central venous catheter exclusion criteria: * absence of consent * less than 18 years patients * gastro-intestinal dysfunction * major burns \>20% body surface * admission for cardio-respiratory arrest or brain injury * pregnancy or lactation * diabetes mellitus (i and ii) * statin treatment * patient on parenteral nutrition * absence of central venous line * participation in another interventional trial

Keywords: body composition muscle mass protein metabolism enteral nutrition icu
safety, tolerability, and efficacy of isis-ptp1brx in type 2 diabetes

Conditions: Type 2 Diabetes Mellitus; Obese

Summary: the purpose of this study is to evaluate the safety, tolerability, and efficacy of isis-ptp1brx + oral antidiabetic drug/s (metformin and/or sulfonylurea) versus placebo + oral antidiabetic drug/s.


Eligibility criteria:
inclusion criteria: * body mass index (bmi) \>/= 27 kg/m2 * hba1c between 7.5% and 10.5% (inclusive) * c-peptide (fasting) greater than or equal to 500 pmol/l * on stable dose of metformin alone or in combination with a stable dose of sulfonylurea for \>/= 3 months prior to screening, and remain on stable dose throughout the study * agree to conduct home-based (fasted) blood glucose testing as directed exclusion criteria: * clinically significant abnormalities in medical history or physical exam * serum creatinine \> uln at screening * clinical signs or symptoms of liver disease, acute or chronic hepatitis, or alt or ast \> 1.5x uln at screening * history of renal transplantation or renal dialysis * gfr \< 60 ml/min at screening * history of diabetic ketoacidosis * history of greater than 3 episodes of severe hypoglycemia within 6 months of screening * allergy to sulfur containing drugs * treatment with other drugs or medications not allowed per study specific disallowed concomitant medicines * any other significant illness or condition that may interfere with the patient participating or completing the study * inability or unwillingness to comply with protocol or study procedures

Keywords: type 2 diabetes mellitus t2dm
cryotechnique as a diagnostic and therapeutic tool of endobronchial tumors

Conditions: Cryotherapy Effect; Bronchial Neoplasms

Summary: this study was to assess the diagnostic yield and the safety of bronchoscopic cryotechniques in the management of endobronchial tumors.

novel flexible cryoprobes were introduced for tissue sampling during bronchoscopy. employing this approach, the sample is collected when frozen, with the tissue attached to the frozen end of the probe. this approach enables the retrieval of larger tissue samples from endobronchial lesionsendobronchial cryotherapy is employed to treat individuals with obstructive central bronchial lung cancers. it has been demonstrated to effectively recanalize obstructed respiratory passages, alleviate symptoms, and improve the quality of life for patients in advanced stagesthis study aimed to assess the effectiveness and safety of using bronchoscopic cryotechniques for diagnosing and treating endobronchial malignancies.

Eligibility criteria:
inclusion criteria: * patients with radiologically suspected endobronchial masses exclusion criteria: * patients with contraindications to bronchoscopy. * uncorrected coagulopathy (if the international normalized ratio (inr) is more than 1.5). * severe refractory hypoxemia (even after administering the highest possible dose of oxygen, the partial pressure of oxygen ("pao2") stays below 70 mm hg. * hypoventilation with hypercapnia (type 2 respiratory failure). * severe pulmonary hypertension \> 55 mmhg by echocardiography. * hemodynamic instability.

Keywords: cryobiopsy cryotherapy endobronchial tumors
neoadjuvant afatinib in early stage non small cell lung cancer.

Conditions: Non Small Cell Lung Cancer

Summary: this is a multicenter, randomized, 1:1, non-comparative phase ii trial. patients with early stage nsclc will be randomized between arm a: neoadjuvant afatinib followed by surgery and arm b: immediate surgery with curative intent.

this is a multicenter, prospective, open-label, randomized, non-comparative, two-arm phase ii trial aiming to evaluate afatinib treatment in pre-operative setting in patients with egfr mutated nsclc. after signing of the informed consent, patients will be registered and screened for eligibility and upon confirmation of all eligibility criteria, patients will be randomized 1:1 to: * arm a: once daily afatinib at a dose of 40 mg for 8 weeks followed by surgery with curative intent (anatomical resection and systematic lymph node dissection). * arm b: immediate surgery with curative intent (anatomical resection and systematic lymph node dissection). response evaluation in the pre-operative arm will be performed through ct scans at baseline, 4 and 8 weeks. the first 5 patients enrolled in arm a will be part of a safety run-in to check that afatinib treatment doesn't delay surgery.

Eligibility criteria:
inclusion criteria: histological or cytological diagnosis of nsclc; * patients considered operable and with resectable tumor with curative intent (anatomical resection and systematic lymph node dissection) based on evaluation by a thoracic multi-disciplinary team composed of at least a thoracic surgeon, oncologist and radiologist; * stage i-iii (t1a-3, n0-1, m0 according to uicc version 7) nsclc by local staging criteria potentially treatable by radical (curative) surgery. patients with t1 tumor at baseline will be limited to 20%; * radiologically measurable disease according to recist criteria 1.1; assessed by chest and upper abdomen ct scan within 2 weeks (+1 week) prior to registration); brain ct scan or mri according to local practice; * no prior treatment for nsclc is allowed; * adequate tissue in terms of quality and quantity for egfr local testing. exclusion criteria: * no adequate bone marrow function within 2 weeks prior to randomization * no adequate liver function. patients with gilbert's syndrome total bilirubin must be below 4 times institutional upper limit of normal; within 2 weeks prior to randomization * no adequate renal function within 2 weeks prior to randomization * known positivity to human immunodeficiency virus (hiv), hepatitis b or hepatitis c; * known history of allergic reactions attributed to compounds of similar chemical or biological composition; * history of a hematologic or primary solid tumor malignancy, unless no evidence of that disease for 5 years, except pt1-2 prostatic cancer gleason score \< 6, superficial bladder cancer, non melanoma skin cancer or carcinoma in situ of the cervix;

Keywords: nsclc early stage phase ii randomized egfr mutated
sclerotherapy and candida antigen in treatment of common warts

Conditions: Common Wart

Summary: this study aims to evaluate the efficacy and safety of intralesional injections of candida antigen, polidocanol sclerotherapy and combined candida antigen with polidocanol in treatment of patients with common warts.

warts are benign proliferations of skin and mucosa caused by the human papillomavirus . currently, more than 100 types of human papillomavirus have been identified, which is a non-enveloped double-stranded, circular, supercoiled dna virus enclosed in an icosahedral capsid and comprising 72capsomers immunotherapy in wart treatment is a type of biological therapy that uses substances to stimulate the immune system to help the body fight infected cells. this includes topical agents as imiquimod, sineacatechins, and intralesional immunotherapy which become more preferred treatment line for several types of warts, several injectable agents have been examined such as vitamin d3, interferon alpha 2b and skin test antigens such as the candida antigen and purified protein derivatives or systemic immunotherapy as zinc, cimetidine. intralesional candida antigen has been successfully used in the treatment of warts with the potential advantages of promising efficacy, low cost, high safety profile, simple easy injection, association with distant response, absence of scarring and pigmentary changes and less pain than destructive therapies, and low or absent recurrence rates treatments targeting and obliterating blood vessels such as pulsed dye laser and photodynamic therapy have been used in the treatment of common warts. based on these observations, and the previous reports of the successful use of polidocanol in the treatment of various skin conditions with vascular components, the intralesional polidocanol therapy could be helpful in the treatment of common warts through the thrombotic occlusion and obliteration of blood vessels within the wart. the complete and partial cure rates after intralesional polidocanol 3% injection in plantar warts were 60% and 25%, respectively

Eligibility criteria:
inclusion criteria: * age group: \>18years. * confirmed diagnosis by clinical and dermoscopic examination of common wart will be made. exclusion criteria: * patients who receive any treatment for wart in the last month before the study. * patients with history of renal or liver disease. * patients with any evidence of bleeding diathesis, vaso-occulusive or thrombo-embolic disorders. * pregnant and lactating females. * patients who receive immunosuppressive therapy. * patients' refusal. * patients with history or evidenced hypersensitivity to any component used in this study.
flex arteriovenous access registry

Conditions: Peripheral Artery Disease; Arteriovenous Fistula Stenosis; Arteriovenous Graft Stenosis

Summary: evaluation of the flex vessel prep system combined with angioplasty in the treatment of arteriovenous access stenosis.


Eligibility criteria:
inclusion criteria: 1. hemodialysis patient currently scheduled to undergo an intervention of their arteriovenous fistula or graft due to clinical or hemodynamic abnormalities. 2. the patient is ≥18 years of age. patient is legally competent, has been informed of the study, voluntarily agrees to participate, and has signed the inform consent form. 3. the patient has a reasonable expectation of remaining on hemodialysis for 12 months. 4. the patient understands the study and is willing and able to comply with follow-up requirements. 5. the patient is willing to provide informed consent. exclusion criteria: 1. the patient has a known or suspected systemic infection. 2. the patient has a known or suspected infection of the hemodialysis graft. 3. the patient has an untreatable allergy to radiographic contrast material. 4. in the opinion of the operating physician, the patient's hemodialysis access is unsuitable for endovascular treatment.
intravenous acetaminophen for postoperative delirium in older patients recovering from major noncardiac surgery

Conditions: Delirium in Old Age

Summary: investigators propose this multi-center randomised controlled study to test the preventive effect of intravenouse acetaminophen in delirium over 5 postoperative days among older patients recovering from major non-cardiac surgery.

delirium is a common complication in elderly patients after major surgeries and can lead to poor outcomes such as neurocognitive decline. acetaminophen is a widely used adjuvant for perioperative multimodal analgesia. it can effectively alleviate postoperative pain, promote opioid-sparing and exert anti-neuroinflammatory response, showing strong potential for preventing postoperative delirium. there is evidence that intravenous acetaminophen reduces delirium in older patients following cardiac surgery, but its effectiveness is inconclusive among non-cardiac surgical patients. investigators propose this multi-center, randomized, placebo-controlled, parallel-group trial in patients aged \>65 years old scheduled for non-cardiac major surgery with general anesthesia expected to last at least 2 h. a total of 1930 elderly patients will be enrolled and randomized at 1:1 ratio to acetaminophen or saline placebo groups, stratified by age, education level, and trial site with random-sized blocking. acetaminophen or saline will be given when the surgical suture begin at the end of surgery and thereafter a total of 7 doses within 48h after surgery. the primary outcome will be the incidence of delirium, assessed twice daily, through the five postoperative days. secondary outcomes will include pain scores with movement, opioid use within the first 48 postoperative hours, severity of delirium, icu and hospital lengths of stay.

Eligibility criteria:
inclusion criteria: 1. age ≥ 65 years. 2. scheduled for non-cardiac major surgery with general anesthesia that is expected to last more than 2h. 3. asa physical status i-iii. 4. weight \>50 kg. 5. written informed consent. exclusion criteria: 1. pre-existing neuropsychiatric diseases (alzheimer's disease, schizophrenia, parkinson's disease, seizures, etc.). 2. pre-existing cognitive impairment (mmse\<18). 3. preoperative delirium. 4. severe circulatory instability (preoperative left ventricular ejection fraction less than 30%, unstable angina, severe coronary artery disease, sick sinus syndrome, etc.). 5. contraindication to the acetaminophen use, including serum creatinine \> 177µmol/l or aminotransferses \> 3 times the upper limit of normal. 6. alcohol or drug abuse within a year before surgery. 7. inability to communicate because of severe visual/auditory dysfunction or language barrier.

Keywords: postoperative delirium acetaminophen elderly patient
memantine for disability in amyotrophic lateral sclerosis (medals)

Conditions: Amyotrophic Lateral Sclerosis

Summary: the purpose of this trial is to study the effect of memantine (uncompetitive, moderate affinity, nmda receptor antagonist that binds to the nmda receptor channel, and regulates the calcium influx into the neurons), a drug used to treat alzheimer´s disease, on the progression of amyotrophic lateral sclerosis (als). memantine is added to riluzole (the single drug approved to treat als).

phase 2/3 trial in als patients double-blinded, parallel, randomized (2 blocs, bulbar/spinal onset) memantine + riluzole x placebo + memantine inclusion criteria: * \< 75 years at disease onset * \< 3 years of disease progression * als-frs \> 24 * fvc \> 60 * probable or definite disease (revised el escorial criteria) * no other medical condition * normal blood tests * regular medication on riluzole \> 1 month * nerve conduction studies ruling out conduction block * emg with widespread loss of motor units (revised el escorial criteria) * at least one hand with adm strength \> 2 on mrc scale duration - 2 years evaluation - every 3 months primary outcome - als-frs secondary -sf36, hamilton depression scale, motor unit number estimation, neurophysiological index, strength (clinical evaluation); side-effects intention to treat analysis 60 patients number estimated for 50% change in decline rate of als-frs

Eligibility criteria:
inclusion criteria: * definite or probable disease - revise el escorial criteria * normal blood tests * riluzole treatment during 1 month or more * emg in accordance with el escorial criteria exclusion criteria: * other diseases (such as pnp) * both adm muscles \< 3 on mrc scale * conduction block on nerve conduction tests * disease duration \> 3 years * als-frs \< 25 * forced vital capacity - \<60%

Keywords: amyotrophic lateral sclerosis motor neuron disease memantine clinical trial
effects of a dietary approach to iron deficiency in premenopausal women affected by celiac disease

Conditions: Celiac Disease; Iron Deficiency (Without Anemia)

Summary: anemia and sideropenia are a common effect of untreated celiac disease. in a portion of patients a certain degree of hypoferritinemia persist after the diagnosis, despite a good compliance and clinical response to gluten-free diet. these patients are usually premenopausal women in whom the cyclic menstrual bleeding and the oral iron intake are not balanced. the aim of the study is to compare the efficacy of a pharmacological therapy, frequently not tolerated, and a dietary approach through a iron-rich diet in this subset of patients.


Eligibility criteria:
inclusion criteria: * celiac patients on gluten free diet since 1 year * iron deficiency (ferritin \<15 ng/l or ferritin 15-20 + transferrin saturation \<15%) exclusion criteria: * allergy to iron supplementation * anemia * pregnancy or breastfeeding * menopause * organic or psychiatric diseases
scapular mobilization on inspiratory capacity of post-cabg patients

Conditions: CABG

Summary: to determine the effects of scapular mobilization on pulmonary functions of post-cabg patients.


Eligibility criteria:
inclusion criteria: * cad patients undergone cabg surgery (post-op. day#. 01). * both genders (male and female). * aged between 40 to 70 years . * patient having oxygen saturation (spo2) of more than or equal to 90% with 25% of fraction of inspired oxygen (fio2) - (possibly nasal cannula inserted). exclusion criteria: * patients with low glasgow coma scale (gcs) score (less than 15). * patients having inspiratory capacity of 3500ml and above. * patients on ventilator.
registry evaluation of a double balloon accessory device

Conditions: Adenomatous Polyp of Colon

Summary: this study is collecting standard of care information pertaining to the use of the accessory device and patient outcomes when this double balloon accessory device is used during endoscopic procedures in the colon.


Eligibility criteria:
inclusion criteria: 1. patients scheduled for endoscopic removal of suspected adenomatous benign polyps(s) 2. patients capable of giving informed consent in english 3. no medical contraindication to endoscopic mucosal resection or endoscopic submucosal disection exclusion criteria: 1. no patients less than 18 years of age. 2. any contraindication to colonoscopy with due to subject's colon anatomy (i.e. stricture) 3. history of open or laparoscopic colorectal surgery 4. history of inflammatory bowel disease
role of endocrine disruptors in thyroid cancer

Conditions: Endocrine Disruptor Chemicals; Thyroid Cancer

Summary: the relationship between human exposure to edcs and tc is poorly investigated and still unclear. the aim of this study is to evaluate the possible role of old and new generation endocrine disruptors in thyroid cancer. the primary aim is to evaluate the difference in the average levels of the main endocrine disruptors (pfas, including: pfoa, pfos, pfda, pfuna, pfhps and possibly subsequently other categories, such as bisphenols, phthalates, parabens, pcbs, flame retardants) between patients with and without a diagnosis of thyroid cancer through highly sensitive, selective and precise mass spectrometry methods, such as liquid chromatography combined with tandem mass spectrometry (lc-ms / ms). the secondary aim is to evaluate the relationship between the concentrations of endocrine disruptors and some anamnestic variables studied (for example the type of diet, the use of personal care products).


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of thyroid cancer in the last 5 years (arm a) * patients without a diagnosis of thyroid cancer will match patients included in arm a exclusion criteria: * subjects under 18 years old * patients unable to sign the informed consent or questionnaires
nano fat injection with or without fractional carbon dioxide laser in acne scars

Conditions: Acne Scars - Atrophic

Summary: assessment of nano fat grafting combined with carbon dioxide laser resurfacing versus nano fat grafting alone in treating facial atrophic acne scars

acne scars is a world wide problem .though lots of treatment exists still mo gold standard for treatment of acne scars in this study. assessment of nano fat grafting combined with carbon dioxide laser resurfacing versus nano fat grafting alone in treating facial atrophic acne scars

Eligibility criteria:
inclusion criteria: * patients older than 18 years who attend the outpatient clinics of dermatology and plastic surgery departments, assiut university hospital, with moderate to severe atrophic facial acne scars on both cheeks, as assessed using the goodman and baron qualitative scar grading system (12), will be enrolled in the study. exclusion criteria: * include: pregnancy or lactation; active acne, history of deep chemical peeling or filler injection in the previous 6 months, history of keloid or hypertrophic scar formation; use of isotretinoin in the previous 6 months; active infection in the treatment area; bleeding tendencies; history of herpes simplex or herpes zoster infection on the face; and patients with unrealistic expectations.